“The COVID-19 crisis has once more highlighted the need for incentivizing investment and innovation—and thus, for patent laws that duly “promote” and protect such “progress,” precisely as our Founders envisioned,” writes Chief Judge Paul Michel, now retired from the Federal Circuit. As he so often is, Judge Michel is absolutely correct. Many are asking why testing for the coronavirus that causes COVID-19 has been slow to roll out, and why tests in many countries are inaccurate. Those familiar with U.S. patent laws understand the problem. There has been a deemphasis on medical diagnostics in America as the result of a series of Supreme Court and Federal Circuit rulings, coupled with Congressional inaction.
Recent Posts
- IP as a Force for Good: A Conversation with WIPO Director General Daren Tang
- Stewart Defends Hands-On Approach as Squires Confirmation Looms
- Former USPTO Solicitor Urges Squires Confirmation, Accuses Acting Director of Overreach
- Other Barks & Bites for Friday, September 12: Novartis Loses Challenge to IRA Drug Price Negotiation Program; Lutnick Wants a Share of University IP Licensing; and EUIPO Announces First Copyright Conference
- Government Taking a Cut of University Royalties Would Threaten Bayh-Dole’s ROI